JP2008506709A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008506709A5 JP2008506709A5 JP2007521684A JP2007521684A JP2008506709A5 JP 2008506709 A5 JP2008506709 A5 JP 2008506709A5 JP 2007521684 A JP2007521684 A JP 2007521684A JP 2007521684 A JP2007521684 A JP 2007521684A JP 2008506709 A5 JP2008506709 A5 JP 2008506709A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- peptidomimetic
- seq
- compound
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 t-butoxycarbonyl group Chemical group 0.000 claims 16
- 239000000816 peptidomimetic Substances 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 4
- 150000002632 lipids Chemical class 0.000 claims 4
- 125000006239 protecting group Chemical group 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 150000008574 D-amino acids Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940127088 antihypertensive drug Drugs 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 1
- 239000002327 cardiovascular agent Substances 0.000 claims 1
- 229940125692 cardiovascular agent Drugs 0.000 claims 1
- 239000003405 delayed action preparation Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58872204P | 2004-07-16 | 2004-07-16 | |
| US60/588722 | 2004-07-16 | ||
| PCT/US2005/025182 WO2006020040A2 (en) | 2004-07-16 | 2005-07-15 | Apolipoprotein a1 mimetics and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008506709A JP2008506709A (ja) | 2008-03-06 |
| JP2008506709A5 true JP2008506709A5 (enExample) | 2008-09-04 |
| JP5048486B2 JP5048486B2 (ja) | 2012-10-17 |
Family
ID=35907926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007521684A Expired - Fee Related JP5048486B2 (ja) | 2004-07-16 | 2005-07-15 | アポリポタンパク質a1の模倣物とその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US7569546B2 (enExample) |
| EP (1) | EP1771473B1 (enExample) |
| JP (1) | JP5048486B2 (enExample) |
| KR (1) | KR101185609B1 (enExample) |
| CN (1) | CN101076541A (enExample) |
| AU (1) | AU2005275009B2 (enExample) |
| BR (1) | BRPI0513402A (enExample) |
| CA (1) | CA2574007A1 (enExample) |
| IL (1) | IL180733A (enExample) |
| NO (1) | NO20070876L (enExample) |
| TW (1) | TWI377066B (enExample) |
| WO (1) | WO2006020040A2 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7199102B2 (en) * | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
| US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| BRPI0513402A (pt) * | 2004-07-16 | 2008-05-06 | Tufts College | miméticos de apolipoproteìna a1 e usos dos mesmos |
| US20060205669A1 (en) * | 2004-09-16 | 2006-09-14 | The Regents Of The University Of California | G-type peptides and other agents to ameliorate atherosclerosis and other pathologies |
| RU2414236C2 (ru) | 2004-12-06 | 2011-03-20 | Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье | Способ улучшения структуры и/или функций артериол |
| US20080293639A1 (en) * | 2005-04-29 | 2008-11-27 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| EA200900786A1 (ru) * | 2005-04-29 | 2009-10-30 | Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье | Пептид в качестве лекарственного средства и способ лечения патологий, связанных с воспалительными процессами, посредством пептида |
| US8163699B2 (en) * | 2006-06-01 | 2012-04-24 | Montreal Heart Institute | Method for the treatment of valvular disease |
| EP2049137A4 (en) * | 2006-08-08 | 2013-05-01 | Univ California | SALICYLANILIDES AS AMPLIFIERS OF THE ORAL RELEASE OF THERAPEUTIC PEPTIDES |
| CA2672131C (en) * | 2006-12-13 | 2016-06-07 | The Regents Of The University Of California | Potent and selective mediators of cholesterol efflux |
| JP2010537638A (ja) | 2007-08-28 | 2010-12-09 | ユーエービー リサーチ ファウンデーション | 合成アポリポ蛋白質e模倣ポリペプチドおよび使用方法 |
| AU2008296478B9 (en) | 2007-08-28 | 2015-03-19 | The Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
| US20110178029A1 (en) * | 2007-09-14 | 2011-07-21 | Ambrx, Inc. | Modified Human Apolipoprotein A-1 and Their Uses |
| US9173890B2 (en) | 2007-09-20 | 2015-11-03 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| US7985728B1 (en) | 2007-09-20 | 2011-07-26 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| US7985727B1 (en) | 2007-09-20 | 2011-07-26 | Abbott Cardiovascular Systems Inc. | Apo A-I mimetic peptides and methods of treatment |
| US20110020242A1 (en) * | 2007-12-12 | 2011-01-27 | Gang Zheng | High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles |
| AU2014268255B2 (en) * | 2009-02-16 | 2016-04-21 | Cerenis Therapeutics Holding Sa | Apolipoprotein a-i mimics |
| DK2396017T3 (en) | 2009-02-16 | 2015-09-14 | Cerenis Therapeutics Holding Sa | Apolipoprotein A-I-mimetika |
| EP2582379A4 (en) * | 2010-06-15 | 2013-12-04 | Matthew C Lawyer | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROSIS |
| HUE042314T2 (hu) * | 2011-02-07 | 2019-06-28 | Cerenis Therapeutics Holding Sa | Lipoprotein komplexek és azok gyártása és alkalmazásai |
| CN105050614B (zh) | 2013-03-15 | 2019-04-05 | 加利福尼亚大学董事会 | 刺激胆固醇流出的具有降低的毒性的肽 |
| CN103910802B (zh) * | 2014-04-24 | 2017-01-11 | 华中科技大学 | 一种促进树突细胞摄取抗原肽的多肽、促进树突细胞摄取抗原肽的纳米颗粒及其应用 |
| CA2954475C (en) | 2014-07-31 | 2023-05-16 | Uab Research Foundation | Apoe mimetic peptides and higher potency to clear plasma cholesterol |
| FR3026409B1 (fr) * | 2014-09-26 | 2018-03-30 | Centre National De La Recherche Scientifique (Cnrs) | Procede de criblage de molecules interferentes |
| EP3273944B1 (en) * | 2015-03-25 | 2024-11-20 | The Regents of The University of Michigan | Compositions and methods for delivery of biomacromolecule agents |
| EP3471778A4 (en) | 2016-06-20 | 2020-02-19 | The Regents of The University of Michigan | COMPOSITIONS AND METHODS FOR ADMINISTERING BIOMACROMOLECULAR AGENTS |
| TW202130652A (zh) | 2017-01-19 | 2021-08-16 | 美國衛生與公眾服務部 | Apoc-ii擬肽 |
| EP4135747A1 (en) | 2020-04-16 | 2023-02-22 | Abionyx Pharma SA | Methods for treating acute conditions using lipid binding protein- based complexes |
| JP2023543498A (ja) | 2020-10-01 | 2023-10-16 | アビオニクス ファーマ エスエー | 脂質結合タンパク質ベースの複合体を使用した、眼疾患を治療するための方法 |
| JP2024514154A (ja) | 2021-04-15 | 2024-03-28 | アビオニクス ファーマ エスエー | 臓器保存溶液における脂質結合タンパク質ベースの複合体の使用 |
| EP4504233A1 (en) | 2022-04-06 | 2025-02-12 | Abionyx Pharma SA | Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes |
| EP4504150A1 (en) | 2022-04-06 | 2025-02-12 | Abionyx Pharma SA | Methods for treating eye diseases using lipid binding protein-based complexes |
| CN120344255A (zh) | 2022-06-10 | 2025-07-18 | 阿比奥尼克斯制药公司 | 使用基于脂质结合蛋白的复合物治疗过度炎性病症的方法 |
| EP4536269A2 (en) | 2022-06-10 | 2025-04-16 | Abionyx Pharma SA | Methods for treating acute conditions using lipid binding protein-based complexes |
| AU2024207875A1 (en) | 2023-01-13 | 2025-07-24 | Abionyx Pharma Sa | Lipid binding protein molecule therapy |
| WO2025093929A1 (en) | 2023-10-31 | 2025-05-08 | Abionyx Pharma Sa | Lipid binding protein molecule therapy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2214247C (en) * | 1995-03-14 | 2004-02-10 | Praecis Pharmaceuticals Incorporated | Modulators of amyloid aggregation |
| US6664230B1 (en) | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US7105635B2 (en) * | 2002-06-04 | 2006-09-12 | The University Of Toledo | Cyclic beta-sheet peptides useful as apoptotic/cytotoxic cancer agents |
| BRPI0513402A (pt) * | 2004-07-16 | 2008-05-06 | Tufts College | miméticos de apolipoproteìna a1 e usos dos mesmos |
| US20060205669A1 (en) * | 2004-09-16 | 2006-09-14 | The Regents Of The University Of California | G-type peptides and other agents to ameliorate atherosclerosis and other pathologies |
| RU2414236C2 (ru) * | 2004-12-06 | 2011-03-20 | Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье | Способ улучшения структуры и/или функций артериол |
-
2005
- 2005-07-15 BR BRPI0513402-1A patent/BRPI0513402A/pt not_active IP Right Cessation
- 2005-07-15 EP EP05772288A patent/EP1771473B1/en not_active Expired - Lifetime
- 2005-07-15 CN CNA2005800311531A patent/CN101076541A/zh active Pending
- 2005-07-15 KR KR1020077003757A patent/KR101185609B1/ko not_active Expired - Fee Related
- 2005-07-15 WO PCT/US2005/025182 patent/WO2006020040A2/en not_active Ceased
- 2005-07-15 AU AU2005275009A patent/AU2005275009B2/en not_active Ceased
- 2005-07-15 CA CA002574007A patent/CA2574007A1/en not_active Abandoned
- 2005-07-15 JP JP2007521684A patent/JP5048486B2/ja not_active Expired - Fee Related
- 2005-07-15 US US11/182,490 patent/US7569546B2/en not_active Expired - Fee Related
- 2005-07-19 TW TW094124388A patent/TWI377066B/zh not_active IP Right Cessation
-
2007
- 2007-01-16 IL IL180733A patent/IL180733A/en not_active IP Right Cessation
- 2007-02-15 NO NO20070876A patent/NO20070876L/no not_active Application Discontinuation
-
2009
- 2009-05-21 US US12/469,942 patent/US8124580B2/en not_active Expired - Fee Related
-
2012
- 2012-02-28 US US13/406,880 patent/US20120259091A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008506709A5 (enExample) | ||
| JP5683951B2 (ja) | 長期間作用性ペプチド類似体のための組成物 | |
| JP2006508179A5 (enExample) | ||
| AU2007284801A1 (en) | Salicylanilides enhance oral delivery of therapeutic peptides | |
| WO2012050227A1 (en) | Peptide derivative | |
| JP2011518179A5 (enExample) | ||
| RU2007110981A (ru) | Урокортин iii и его использование | |
| CA2697504A1 (en) | Salicylanilide modified peptides for use as oral therapeutics | |
| RU2009110452A (ru) | Галеновые составы алискирена | |
| AR025307A1 (es) | Compuesto de liberacion sostenida de un peptido, microparticulas, composicion farmaceutica y el uso de dicho compuesto para la fabricacion de un medicamento | |
| JP2008522980A5 (enExample) | ||
| DK2783697T3 (en) | VIP Fragments and uses thereof | |
| JP2009523156A5 (enExample) | ||
| JP2007506713A (ja) | 例えば、抗血管新生活性を有するペプチドおよび治療におけるその適用 | |
| JP2010513311A5 (enExample) | ||
| ES2349153T3 (es) | Inhibidores del virus de la hepatitis c. | |
| JP5421257B2 (ja) | プラスミノーゲン活性化因子阻害物質1由来のペプチドおよびその使用 | |
| SK150196A3 (en) | Peptides with immunomodulatory effects, pharmaceutical formulations containing them and their use | |
| JP2005514385A (ja) | プリオン阻害ペプチド及びその誘導体 | |
| CN101657465B (zh) | 肽、组合物及其应用 | |
| CN114364691B (zh) | 作为纤维化基质积累的抑制剂的肽 | |
| ES2254938T3 (es) | Mutantes de quimioquinas que poseen biodisponibilidad oral mejorada. | |
| US6596692B1 (en) | Substance P analogs for the treatment of cancer | |
| JP2014198711A (ja) | Ct阻害4価ペプチドおよびコレラ治療薬 | |
| JP4332618B2 (ja) | 抗hiv剤 |